Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel J. DeAngelo, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Daniel DeAngelo and Kimberly Stegmaier.
Connection Strength

1.350
  1. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313.
    View in: PubMed
    Score: 0.174
  2. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 06 27; 213(7):1285-306.
    View in: PubMed
    Score: 0.167
  3. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10; 25(2):226-42.
    View in: PubMed
    Score: 0.142
  4. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
    View in: PubMed
    Score: 0.139
  5. SYK regulates mTOR signaling in AML. Leukemia. 2013 Nov; 27(11):2118-28.
    View in: PubMed
    Score: 0.133
  6. The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47.
    View in: PubMed
    Score: 0.123
  7. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
    View in: PubMed
    Score: 0.105
  8. Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205.
    View in: PubMed
    Score: 0.101
  9. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005 Oct 15; 106(8):2841-8.
    View in: PubMed
    Score: 0.078
  10. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021 03 31; 13(587).
    View in: PubMed
    Score: 0.058
  11. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 03 07; 10(431).
    View in: PubMed
    Score: 0.047
  12. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.042
  13. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.